ClinicalTrials.gg
CompletedNCT06348511Updated Apr 4, 2024

XTics - A Gamified Enhancer of Non-Pharmacological Interventions in Tic Disorders

An interventional study of XTics in Tic Disorders, sponsored by Tel-Aviv Sourasky Medical Center. Completed at 1 site in Israel. Open to participants aged 7 Years to 15 Years. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jul 2022, registered Mar 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
7 Years to 15 Years
Sex
All
01

Study summary

The investigators developed a neuroscientifically-informed gamified tic-therapy platform. The investigators previously identified tic-triggering elements in movies and video games. Next, the investigators employed these elements to generate and validate a gamified intervention protocol, which is based on a video game the investigators designed (called XTics). The study tests the efficacy of the gamified tool integrated in an exposure and response prevention (ERP) protocol to enhance both patient's compliance and clinical outcome.

Read the detailed description

Background: Behavioral treatments are recommended as first-line interventions for tic disorders (TDs) in children and adults, which affect 2.99% of children. However, the effectiveness of these interventions is often undermined by the limited compliance especially of young individuals with the demanding treatment protocols. Addressing this issue, gamification of the treatment can enhance engagement and adherence in children. In the context of TDs, gamification provides significant additional benefits, particularly robust immediate feedback. This feedback can counteract the negative reinforcement processes, wherein the tic, believed to relieve the unpleasant premonitory urge, becomes consolidated. The investigators developed a gamified Protocol XTics, which leverages the previously untapped potential of combining various tic triggers with immediate reinforcement of tic suppression. The investigators evaluated the clinical value of XTics, focusing particularly on the benefits of immediate reward contingency in enhancing tic suppression performance.

Methods: The investigators developed a game incorporating tic triggers validated in a prior study. In one version of the game, its progression was influenced by real-time input from an experimenter who continuously monitored the participant's tics, rewarding tic suppression with favorable game outcomes. Employing a crossover design, the investigators trained 35 participants, aged 7-15, in both this version and another where the game's progression was independent of tic suppression. Following two online group Exposure and Response Prevention (ERP) training sessions, each participant engaged in three hourly sessions for each of the two conditions. Our evaluation focused on how the overall XTics protocol influenced tics and how this influence differed between the contingent and non-contingent versions of the game.

02

Conditions studied

  • Tic Disorders

Browse trials for

03

In context

Tic Disorders

103 studies on the registry are indexed under Tic Disorders; 23 are open to participants now.

This study's enrollment of 35 is below the median of 50 across 83 interventional studies indexed under Tic Disorders.

Browse Tic Disorders studies →

Lead sponsor

Tel-Aviv Sourasky Medical Center is the lead sponsor of 552 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and youths aged 7-15 years,
  • At least moderate tic severity as indicated by a Yale Global Tic Severity Scale (YGTSS) tic severity score ≥ 11 and
  • Tic frequency of over one tic per minute on average in the screening interview.

Exclusion criteria

Exclusion Criteria:

  • Behavioral treatment for tics in the past 12 months
  • Pharmacological treatment for tics that has not been stable the for the past 6 weeks or with planned changes during study participation
  • Evidence of tics that may produce physical harm to the child
  • A history of psychiatric or neurological disorders requiring hospitalisation or a known cognitive decline.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Immediate and contingent reward (ICR)

    Tic suppression directly affects gameplay, with participants informed that suppressing tics weakens opponents and improves card acquisition. Daily sessions end with feedback on suppression performance relative to that day's baseline.

    Device: XTics

  • Active comparator
    Delayed reward (DR)

    The gameplay does not depend on performance, but participants still receive end-of-session feedback on tic suppression.

    Device: XTics

Interventions

  • DeviceXTics

    XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.

06

What researchers measure

Primary outcomes

  1. The Tic Yale Global Tic Severity Scale (YGTSS)

    A semi-structured clinical interview for assessment of tic severity administered to participants and parents. A clinician rates motor and vocal tics in terms of number, frequency, intensity, complexity and interference as well as overall related impairment over the preceding week. The investigators used YGTSS total tic severity scores.

    Time frame: Baseline (beginning of Week 1), after Phase 1 (beginning of Week 3), and after phase 2 (beginning of Week 5)

  2. The Parent Tic Questionnaire (PTQ)

    A parent-report instrument for assessing tic severity. Tics are rated by frequency and intensity, and are summed to reflect motor, vocal, and total tics scores. PTQ has good internal consistency, good to excellent 2-week temporal stability, and convergent and discriminant validity in a clinic sample.

    Time frame: Baseline, after Phase 1, after Phase 2, after the Booster phase (Week 7), and three months after the treatment termination

  3. Premonitory Urge for Tic Scale (PUTS)

    A self-report scale, which measures tic-related premonitory urges.

    Time frame: Baseline, after Phase 1, after Phase 2

  4. The Subjective Units of Distress Scale (SUDS)

    A self-reported questionnaire assessing the degree of inconvenience attributed to (1) tics and (2) the premonitory urges. Participants provided their ratings on a scale ranging from 0 (indicating absence) to 10 (indicating very severe). The total score was computed by summing the responses from both scales.

    Time frame: By the end of each training day

  5. The "Urge Thermometer"

    A momentary ratings of the experienced magnitude of premonitory urge. The scale consisted of five qualitative descriptions of "0- not at all", "1 - weak", "2 - medium", "3 - strong" and "4- very strong". The child was instructed to pick a number/description to indicate his/her current pre-tic urge

    Time frame: By the end of each training day

  6. Rush Videotape Protocol

    Based on the Rush Videotape Protocol, the investigators recorded the participants under two resting epochs (i.e., performing no specific task) where they were left alone in the room and were instructed to remain seated and wait for 2.5 minutes while avoiding tic suppression. Tics were counted offline by a human rater who also marks epochs in which the participant is hidden or moved in a way that violated the instructions. The investigators used the total Rush scores, which combine scores for tic frequency (number of motor and phonic tics divided by duration of valid recording) and severity of motor and phonic tics.

    Time frame: Week 1, Week 3, Week 5

  7. Tic-to-tic interval

    The duration between two subsequent tics

    Time frame: Week 1, Week 3

Secondary outcomes

  1. The Screen for Child Anxiety Related Emotional Disorders (SCARED)

    A self-report measure for screening anxiety disorders in children. Participants' ratings of their feelings over the previous two weeks are summed into scales of specific anxieties and general anxiety level. SCARED total score is used as a measure of anxiety symptoms. It was filled out by the child with the help of a parent.

    Time frame: Week 1, Week 5

  2. The Children Depression Inventory (CDI)

    A commonly used self-report measure considered useful for screening comorbid depressive disorder in patients with TS (Snijders AH, Robertson MM, Orth M, 2006). The CDI total score is used as a measure of depression symptoms. It is filled out with the child. The investigators used five subscales: Negative Mood, Ineffectiveness, Anhedonia, Negative Self-Esteem, and Interpersonal Problems, as well as the global score.

    Time frame: Baseline and after Phase 2

  3. The Conners' Parent Rating Scale-Revised Long Form (CRS:RL)

    The investigators used the long version, which contains 80 items and estimates different aspects of attention deficit and focus our analysis on the subscales of hyperactivity, inattention, and impulsivity and the composite of ADHD scores. It was filled out by parents or caregivers.

    Time frame: Week 1, Week 5

  4. Obsessive Compulsive Inventory-Child Version (OCI-CV)

    OCI-CV estimates OCD severity across six domains of symptoms: Doubting/Checking, Obsessing, Hoarding, Washing, Ordering, Neutralizing. The total score was computed by summing the responses from all scales. It is filled out with the child. The investigatorslimited our analysis to Doubting/Checking, Obsessing, and total scores.

    Time frame: Week 1, Week 5

  5. The Behavior Rating Inventory of Executive Function (BRIEF)

    BRIEF evaluates children's everyday executive functioning skills. Based on responses to 86 questions, executive functions are assessed across eight domains. The investigators used the composite Behavioral Regulation Index (BRI), which combines the Inhibit, Shift, and Emotional Control subdomains, the Metacognition Index (MI), which combines the subdomains of Organization of Materials and Monitor, and the overall Global Executive Composite (GEC) index, which combines the BRI and MI. BRIEF is filled out by the parents.

    Time frame: Week 1, Week 5

  6. The Emotion Regulation Questionnaire (ERQ)

    A 10-item scale evaluating the respondents' tendency to regulate their emotions by cognitive Reappraisal or by expressive suppression. It was filled out by the child with the help of a parent.

    Time frame: Week 1, Week 5

  7. User Engagement Scale (UES)

    The short Hebrew version of the UES is administered in regard to the game version they played in the past week. In this 12-item questionnaire, four different aspects of the user's experience are estimated using a five-point rating scale:(i) Focused attention, estimating the extent to which the user felt absorbed in the interaction and lost track of time; (ii) Perceived usability, indicating negative affect experienced as a result of the interaction and the degree of control and effort expended; (iii) Aesthetic appeal, i.e., the attractiveness and visual appeal of the interface; (iv) Reward factor, the extent to which the user felt that the experience was satisfying and interesting. The investigators used a composite index, which sums up the scores of UES scales.

    Time frame: Week 3, Week 5

07

Study locations

1 site
  • Sagol Brain Institute, Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Dec 2022, 5 months.

Of 43 non-industry interventional studies with no phase under Tic Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 5 months is below that.

Counting every sponsor, half of 43 studies reached it within 28 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Apr 4, 2024
StartActual
Jul 1, 2022
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348511
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Jul 1, 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Apr 4, 2024

Study contacts

Gal Raz, PhD
principal investigator · Sagol Brain Institute, Tel Aviv Sourasky Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion